These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 15021446)

  • 21. Effect of raloxifene on sexual function in older postmenopausal women with osteoporosis.
    Modugno F; Ness RB; Ewing S; Cauley JA
    Obstet Gynecol; 2003 Feb; 101(2):353-61. PubMed ID: 12576261
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: An open-label, prospective, nonrandomized, observational study.
    Turbí C; Herrero-Beaumont G; Acebes JC; Torrijos A; Graña J; Miguélez R; Sacristán J; Marín F
    Clin Ther; 2004 Feb; 26(2):245-56. PubMed ID: 15038947
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transition from estrogen-progestin to raloxifene in postmenopausal women: effect on vasomotor symptoms.
    Gordon S; Walsh BW; Ciaccia AV; Siddhanti S; Rosen AS; Plouffe L
    Obstet Gynecol; 2004 Feb; 103(2):267-73. PubMed ID: 14754694
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A 12-month comparative study of raloxifene, estrogen, and placebo on the postmenopausal endometrium.
    Goldstein SR; Scheele WH; Rajagopalan SK; Wilkie JL; Walsh BW; Parsons AK
    Obstet Gynecol; 2000 Jan; 95(1):95-103. PubMed ID: 10636510
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Raloxifene versus continuous combined estrogen/progestin therapy: densitometric and biochemical effects in healthy postmenopausal Taiwanese women.
    Tsai KS; Yen ML; Pan HA; Wu MH; Cheng WC; Hsu SH; Yen BL; Huang KE
    Osteoporos Int; 2001 Dec; 12(12):1020-5. PubMed ID: 11846327
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years.
    Jolly EE; Bjarnason NH; Neven P; Plouffe L; Johnston CC; Watts SD; Arnaud CD; Mason TM; Crans G; Akers R; Draper MW
    Menopause; 2003; 10(4):337-44. PubMed ID: 12851517
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of raloxifene on the efficacy of an estradiol-releasing ring for treating vaginal atrophy in postmenopausal women.
    Pinkerton JV; Shifren JL; La Valleur J; Rosen A; Roesinger M; Siddhanti S
    Menopause; 2003; 10(1):45-52. PubMed ID: 12544676
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women.
    Neele SJ; Evertz R; De Valk-De Roo G; Roos JC; Netelenbos JC
    Bone; 2002 Apr; 30(4):599-603. PubMed ID: 11934652
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in postmenopausal women: a randomized clinical trial in Beijing.
    Zheng S; Wu Y; Zhang Z; Yang X; Hui Y; Zhang Y; Chen S; Deng W; Liu H; Ekangaki A; Stocks J; Harper K; Liu J
    Chin Med J (Engl); 2003 Aug; 116(8):1127-33. PubMed ID: 12935394
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized, double-blind, placebo-controlled study on effects of raloxifene and hormone replacement therapy on plasma no concentrations, endothelin-1 levels, and endothelium-dependent vasodilation in postmenopausal women.
    Saitta A; Altavilla D; Cucinotta D; Morabito N; Frisina N; Corrado F; D'Anna R; Lasco A; Squadrito G; Gaudio A; Cancellieri F; Arcoraci V; Squadrito F
    Arterioscler Thromb Vasc Biol; 2001 Sep; 21(9):1512-9. PubMed ID: 11557681
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diary of hot flashes reported upon occurrence: results of a randomized double-blind study of raloxifene, placebo, and paroxetine.
    Simon JA; Chandler J; Gottesdiener K; Lazarus N; He W; Rosenberg E; Wagner JA; Denker AE
    Menopause; 2014 Sep; 21(9):938-44. PubMed ID: 24569618
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials.
    Johnston CC; Bjarnason NH; Cohen FJ; Shah A; Lindsay R; Mitlak BH; Huster W; Draper MW; Harper KD; Heath H; Gennari C; Christiansen C; Arnaud CD; Delmas PD
    Arch Intern Med; 2000 Dec 11-25; 160(22):3444-50. PubMed ID: 11112238
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comparison of raloxifene and calcium plus vitamin D on vaginal atrophy after discontinuation of long-standing postmenopausal hormone therapy in osteoporotic women. A randomized, masked-evaluator, one-year, prospective study.
    Checa MA; Garrido A; Prat M; Conangla M; Rueda C; Carreras R
    Maturitas; 2005 Sep; 52(1):70-7. PubMed ID: 16143228
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomised, double-blind trial comparing raloxifene HCl and continuous combined hormone replacement therapy in postmenopausal women: effects on compliance and quality of life.
    Voss S; Quail D; Dawson A; Bäckström T; Aguas F; Erenus M; The HS; Bonnar J; De Geyter C; Hunter M; Nickelsen T;
    BJOG; 2002 Aug; 109(8):874-85. PubMed ID: 12197366
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical investigation of RAD1901, a novel estrogen receptor ligand, for the treatment of postmenopausal vasomotor symptoms: a phase 2 randomized, placebo-controlled, double-blind, dose-ranging, proof-of-concept trial.
    Hattersley G; Harris AG; Simon JA; Constantine GD
    Menopause; 2017 Jan; 24(1):92-99. PubMed ID: 27575546
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women: A 2-year, placebo-controlled study.
    de Valk-de Roo GW; Stehouwer CD; Meijer P; Mijatovic V; Kluft C; Kenemans P; Cohen F; Watts S; Netelenbos C
    Arterioscler Thromb Vasc Biol; 1999 Dec; 19(12):2993-3000. PubMed ID: 10591680
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of raloxifene, hormone replacement therapy, and placebo on bone turnover in postmenopausal women.
    Weinstein RS; Parfitt AM; Marcus R; Greenwald M; Crans G; Muchmore DB
    Osteoporos Int; 2003 Oct; 14(10):814-22. PubMed ID: 14610642
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Raloxifene as an Adjunctive Treatment for Postmenopausal Women With Schizophrenia: A 24-Week Double-Blind, Randomized, Parallel, Placebo-Controlled Trial.
    Usall J; Huerta-Ramos E; Labad J; Cobo J; Núñez C; Creus M; Parés GG; Cuadras D; Franco J; Miquel E; Reyes JC; Roca M;
    Schizophr Bull; 2016 Mar; 42(2):309-17. PubMed ID: 26591005
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinically favorable effects of raloxifene on bone mineral density and serum lipids: population assessment via bivariate analysis.
    Shah A; Iversen P; Mitlak B
    Prim Care Update Ob Gyns; 1998 Jul; 5(4):165-166. PubMed ID: 10838310
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Raloxifene and hormone replacement therapy increase arachidonic acid and docosahexaenoic acid levels in postmenopausal women.
    Giltay EJ; Duschek EJ; Katan MB; Zock PL; Neele SJ; Netelenbos JC
    J Endocrinol; 2004 Sep; 182(3):399-408. PubMed ID: 15350182
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.